Aytu BioScience ( (AYTU) ) has provided an announcement.
Aytu BioPharma has entered an exclusive agreement with Lupin Pharma Canada to bring their innovative ADHD medications, Adzenys XR-ODT® and Cotempla XR-ODT®, into Canada. These treatments represent convenient options for ADHD patients and are the only orally disintegrating, extended-release tablets approved by the FDA as equivalent to existing medications. The partnership aims to meet the growing demand in the Canadian ADHD market, where there’s been a notable increase in prescriptions and sales. With this move, Aytu expands its global footprint, providing more treatment choices for better management of ADHD.
For an in-depth examination of AYTU stock, go to TipRanks’ Stock Analysis page.
